Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NWT-03** is a novel egg-protein hydrolysate produced by enzymatic digestion of lysozyme from hen egg whites using the endoprotease enzyme Alcalase. It has been identified for its angiotensin-converting enzyme (ACE) inhibitory activity and has shown potential to lower blood pressure, particularly in individuals with mild hypertension. NWT-03 is also investigated for its effects on cardiometabolic markers, arterial stiffness, and cognitive function in people with metabolic syndrome. Its mechanism of action may involve both ACE inhibition and possible inhibition of dipeptidyl peptidase 4 (DPP4), though the precise mechanism for cognitive effects is not fully established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NWT-03.